Medical Journals

Gc-selective Dna-binding Antibiotic, Mithramycin A, Reveals Multiple Points of Control in the Regulation of Hdm2 Protein Synthesis.

Authors:
  • Phillips A
  • Darley M
  • Blaydes J P

From: Cancer Sciences Division, School of Medicine, University of Southampton, MP 824, Southampton General Hospital, Southampton, UK.

Oncogene

  • Publish Date: Jul 2006
  • ISSN: 0950-9232
  • Volume: 25
  • Issue: 30
  • Pages: 4183-93
  • Medium: Print
  • Language: English
  • Citation (JAMA): Phillips A, Darley M, Blaydes J P, et al. Gc-selective Dna-binding Antibiotic, Mithramycin A, Reveals Multiple Points of Control in the Regulation of Hdm2 Protein Synthesis.. Oncogene Jul 2006;25:4183-93

Abstract

The primary role of the Hdm2/Mdm2 oncoprotein is to regulate the levels and activity of the transcription factor p53. Hdm2 synthesis is itself tightly controlled and, as demonstrated by a recently described SNP (SNP309) in the hdm2-P2 promoter, minor variations in Hdm2 expression have phenotypic consequences on radiation sensitivity and cancer predisposition. To further define mechanisms regulating Hdm2 expression, we have investigated the effects of the GC-selective DNA-binding drug, Mithramycin A (MA) on hdm2 mRNA transcription, trafficking, and translation. Firstly we show that the constitutive hdm2-P1 promoter is inhibited by MA. We define, for the first time, the minimal sequence elements that are required for P1-promoter activity and identify those which confer MA sensitivity. Secondly, MA induces p53-dependent transcription from the hdm2-P2 promoter. Thirdly, and critically, MA also inhibits Hdm2 synthesis at the post-transcriptional level, with negative effects on hdm2 mRNA nuclear export and translation. This study highlights the complex interplay between the pathways that regulate Hdm2 protein synthesis in cancer cells, and furthermore emphasizes the export of hdm2 mRNA from the nucleus to the cytoplasm as a key point of control in this process.

Mesh Headings (Keywords): Active Transport, Cell Nucleus, Animals, Antibiotics, Antineoplastic, Base Sequence, Binding Sites, Breast Neoplasms, Cell Line, Tumor, Cell Nucleus, DNA, Neoplasm, Dinucleotide Repeats, Down-Regulation, Female, Gene Expression Regulation, Neoplastic, Humans, Mice, Molecular Sequence Data, Plicamycin, Promoter Regions (Genetics), Proto-Oncogene Proteins c-mdm2, RNA, Messenger


Check for Full Text / PubMed Unique Identifier (PMID): 16501602


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.